81 related articles for article (PubMed ID: 2769786)
1. Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to those of doxorubicin.
Clarke BV; Harwood KV; Donehower R
J Natl Cancer Inst; 1989 Sep; 81(17):1331-2. PubMed ID: 2769786
[No Abstract] [Full Text] [Related]
2. Comparison of the chronic toxicity of piroxantrone, losoxantrone and doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Hasinoff BB; Tran KT; Chadwick DP; Clark JR; Ferrans VJ
Toxicology; 1998 Jun; 128(1):35-52. PubMed ID: 9704904
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone).
Frank SK; Mathiesen DA; Szurszewski M; Kuffel MJ; Ames MM
Cancer Chemother Pharmacol; 1989; 23(4):213-8. PubMed ID: 2924379
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.
Zalupski MM; Benedetti J; Balcerzak SP; Hutchins LF; Belt RJ; Hantel A; Goodwin JW
Invest New Drugs; 1993 Nov; 11(4):337-41. PubMed ID: 8157477
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor.
Savarese DM; Denicoff AM; Berg SL; Hillig M; Baker SP; O'Shaughnessy JA; Chow C; Otterson GA; Balis FM; Poplack DG
J Clin Oncol; 1993 Sep; 11(9):1795-803. PubMed ID: 7689093
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
Albain KS; Liu PY; Hantel A; Poplin EA; O'Toole RV; Wade JL; Maddox AM; Alberts DS
Gynecol Oncol; 1995 Jun; 57(3):407-11. PubMed ID: 7774846
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey.
Berg SL; Balis FM; Godwin KS; Poplack DG
Invest New Drugs; 1993 Nov; 11(4):255-61. PubMed ID: 8157468
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor.
Berg SL; Savarese DM; Balis FM; Denicoff AM; Hillig M; O'Shaughnessy JA; Poplack DG; Cowan KH
Cancer Res; 1993 Jun; 53(11):2587-90. PubMed ID: 7684320
[TBL] [Abstract][Full Text] [Related]
9. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
10. A theoretical study of the intercalative binding of the anti-tumour drug anthrapyrazole to double-stranded oligonucleotides.
Chen KX; Gresh N; Pullman B
Anticancer Drug Des; 1987 Aug; 2(1):79-84. PubMed ID: 3482353
[TBL] [Abstract][Full Text] [Related]
11. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.
Liang H; Wu X; Guziec LJ; Guziec FS; Larson KK; Lang J; Yalowich JC; Hasinoff BB
J Chem Inf Model; 2006; 46(4):1827-35. PubMed ID: 16859314
[TBL] [Abstract][Full Text] [Related]
12. Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.
Talbot DC; Smith IE; Mansi JL; Judson I; Calvert AH; Ashley SE
J Clin Oncol; 1991 Dec; 9(12):2141-7. PubMed ID: 1960556
[TBL] [Abstract][Full Text] [Related]
13. Status of new anthrapyrazole and pyrazoloacridine derivatives.
Berg SL
Crit Rev Oncol Hematol; 1996 Mar; 22(2):79-87. PubMed ID: 8679102
[No Abstract] [Full Text] [Related]
14. Development of a radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in rats.
Nordblom GD; Pachla LA; Chang T; Whitfield LR; Showalter HD
Cancer Res; 1989 Oct; 49(19):5345-51. PubMed ID: 2766301
[TBL] [Abstract][Full Text] [Related]
15. Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.
Curtit E; Chaigneau L; Pauchot J; Nguyen T; Nerich V; Bazan F; Thiery-Vuillemin A; Demarchi M; Pivot X; Villanueva C
Anticancer Res; 2012 Apr; 32(4):1481-3. PubMed ID: 22493389
[TBL] [Abstract][Full Text] [Related]
16. Anthraquinone-sensitized Ca2+ release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy.
Pessah IN; Durie EL; Schiedt MJ; Zimanyi I
Mol Pharmacol; 1990 Apr; 37(4):503-14. PubMed ID: 2157959
[TBL] [Abstract][Full Text] [Related]
17. [Comparative studies on cardiomyopathy induced in rabbits by various anthracyclines and anthraquinone].
Domae N; Kagawa D; Ueda T; Goto M; Tsutani H; Uchida M; Nakamura T; Ando S; Uchino H
Nihon Gan Chiryo Gakkai Shi; 1984 Oct; 19(9):2146-56. PubMed ID: 6597844
[No Abstract] [Full Text] [Related]
18. A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts.
Supino R; Polizzi D; Pavesi R; Pratesi G; Guano F; Capranico G; Palumbo M; Sissi C; Richter S; Beggiolin G; Menta E; Pezzoni G; Spinelli S; Torriani D; Carenini N; Dal Bo L; Facchinetti F; Tortoreto M; Zunino F
Oncology; 2001; 61(3):234-42. PubMed ID: 11574780
[TBL] [Abstract][Full Text] [Related]
19. Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles.
Showalter HD; Fry DW; Leopold WR; Lown JW; Plambeck JA; Reszka K
Anticancer Drug Des; 1986 Apr; 1(2):73-85. PubMed ID: 2453196
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).
Erlichman C; Moore M; Kerr IG; Wong B; Eisenhauer E; Zee B; Whitfield LR
Cancer Res; 1991 Dec; 51(23 Pt 1):6317-22. PubMed ID: 1933893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
